Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Leukemia 1Hematologic Neoplasms 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Hepatocellular 1Biliary Tract Neoplasms 1Barrett Esophagus 1

Interventions

Cyclophosphamide 35fludarabine 18Methotrexate 17fludarabine phosphate 16Dexamethasone 16blinatumomab 15Vincristine 15Cytarabine 14Melphalan 12Tacrolimus 11Etoposide 11pegaspargase 10Whole-Body Irradiation 9Mercaptopurine 9Calcium Dobesilate 9merphos 8Dasatinib 8Busulfan 8Asparaginase 8Thiotepa 7Prednisone 7Mycophenolic Acid 7Leucovorin 7Granulocyte Colony-Stimulating Factor 7Doxorubicin 7prednylidene 6ponatinib 6calaspargase pegol 6Stem Cell Transplantation 6Specimen Handling 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Precursor Cell Lymphoblastic Leukemia-Lymphoma × Itraconazole × Clear all
NCT04067336 2026-05-13

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

Kura Oncology, Inc.

Phase 1/2 Active not recruiting
263 enrolled 1 FDA
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡